Last update July 3, 2022
Increased level of risk
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment., is now set to Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.
Level of risk reviewed on July 1, 2022
102 Plus is a tradename that contains several active ingredients in its composition:
Since each active ingredient of this product may have a different level of risk for breastfeeding, we establish that of the product with higher risk.
For more information (pharmacokinetics, references, ...) tap each active ingredient.
Note: The composition of certain tradenames varies in each country. Please, make sure this is the composition of the tradename you are looking for..
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM